Phase 1/2a study of IL-4/IL-13 immunotherapy

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2025 According to a Neovacs media release, following a successful Phase I/IIa clinical study, the valuation of this mRNA research program in severe asthma could reach 246 - 402 million Euros as reported by the independent firm In Extenso Innovation Croissance. The investments required to complete this study and other related developmental activities are currently estimated at 17 million Euros. The company has initiated contacts with potential partners who can support all or part of this budget.
15 May 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com